Regado Biosciences Inc., of Basking Ridge, N.J., enrolled its first patient in the Phase III REGULATE-PCI trial of its antithrombotic drug, REG1, in patients undergoing percutaneous coronary intervention (PCI). Read More
BOSTON – A lively workshop at EBD Group’s Biopharm America provided attendees with lessons in persuading would-be financiers, as more than two dozen presenters made their 30-second cases to judges, who winnowed the hopefuls to four finalists – each allowed a follow-up, two-minute address – and then a pair of winners. Read More
Shares of Dendreon Corp. (NASDAQ:DNDN) inched up after the European Commission granted marketing authorization in the European Union (EU) for Provenge (sipuleucel-T) in asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC) in men for whom chemotherapy is not yet indicated. Read More
LONDON – The prospects for new drugs to treat cystic fibrosis have improved, following a project to screen thousands of genes to determine which of their protein products affects the function of a molecular sodium channel found on cell membranes. Read More
• Compugen Ltd., of Tel Aviv, Israel, said an immune system checkpoint protein, CGEN-15049, showed an ability to regulate an array of different immune cells, making it a potential target for monoclonal antibody immunotherapy in the area of cancer. Read More
• Teva Pharmaceutical Industries Ltd., of Petach Tikva, Israel, said the FDA approved Treanda (bendamustine HCl) injection, a new formulation of currently approved Treanda, indicated for use in patients with indolent B-cell non-Hodgkins’ lymphoma that has progressed during or within six months of treatment with Rituxan (rituximab, Biogen Idec Inc. and Roche AG) or a Rituxan-containing regimen and in patients with chronic lymphocytic leukemia. Teva acquired Treanda through its 2011 buyout of Cephalon Inc. Read More
• Celtaxsys Inc., of Atlanta, said it completed the first two trials in its Phase I program testing lead candidate CTX-4430, a small-molecule inhibitor of leukotriene A4 hydrolase in development for treating cystic fibrosis (CF) lung disease. Read More
• Ipsen SA, of Paris, reported positive top-line findings from the primary endpoint of the ELECT study assessing the effect of Somatuline Autogel/Somatuline Depot (lanreotide) Injection 120 mg in controlling symptoms in patients with neuroendocrine tumors associated with carcinoid syndrome. Read More
